4 results
The main objective of the study is to investigate the muscarinic cholinergic system as a biological substrate for cognitive dysfunction in schizophrenia. Since cognitive dysfunction is the most disabling and untreatable characteristic of…
To assess the local and systemic safety and tolerability of continued ABBV-951 treatment delivered as a CSCI for 24 hours daily.
Part 1 of the trial (already completed):The primary objective of the research concerned the determination of the Maximum Tolerated Dose (MTD) and/or Maximum Recommended Dose (MRD) of MCLA-128. Which was set to 750mg.The secundary objective of the…
To assess the local and systemic safety and tolerability of ABBV-951 delivered as a CSCI for 24 hours daily for up to 52 weeks.